CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

This study tests an experimental drug called NX-5948 in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments, including BTK and BCL-2 inhibitors. The main goal is to see if the drug can shrink o…

This early-phase study tests a new drug called NX-5948 in adults with advanced B-cell blood cancers (like certain leukemias and lymphomas) that have not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The main goa…

This early-stage study tests a new treatment called UB-VV111 given with rapamycin for people with certain types of blood cancer (large B-cell lymphoma or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The main goal is to check the saf…

This early-phase study is testing a new cell therapy called GT801 in 28 adults with relapsed or hard-to-treat B-cell blood cancers (like leukemia and lymphoma) or autoimmune hemolytic anemia (AIHA). The therapy uses a patient's own immune cells, modified to attack CD19-positive c…

This Phase 2 trial is testing a combination of three drugs—zanubrutinib, obinutuzumab, and venetoclax—in people with previously untreated chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL). The goal is to see if the combo can make …

This early-stage trial tests a new oral drug called NX-2127 in adults with advanced B-cell cancers (like certain leukemias and lymphomas) that have not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to …

This phase 1/2 trial is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells, aiming to improve treatment for people with relapsed or refractory B-cell cancers like lymphoma and leukemia. The study will enroll up to 100 adults and eva…

This study tests whether giving a second course of venetoclax plus obinutuzumab can control chronic lymphocytic leukemia (CLL) when it comes back after initial treatment. About 75 adults whose CLL returned after prior successful therapy will receive the drug combination for up to…

This program offers early access to venetoclax, a targeted cancer pill, for people with certain blood cancers like leukemia or lymphoma who have no other good treatment options. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved in all…

This phase 2 trial tests the drug venetoclax (a pill) in 110 people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study includes two groups: those with a specific genetic change (17p deletion) and those who have failed oth…

This phase 2 trial is testing whether combining zanubrutinib and venetoclax can clear even trace amounts of cancer in people with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study enrolls 45 adults whose disease has returned afte…

This study watches people with blood cancers like CLL who take BTK inhibitors or venetoclax to see how these drugs affect heart rhythm. Researchers will use EKGs, stress tests, and heart monitors to track abnormal rhythms and sudden death risk. The goal is to better understand an…

This study looks at whether targeted cancer drugs called TKIs affect brain health and well-being in people with chronic leukemia. Researchers will compare 400 patients who receive TKI therapy to those who do not. The goal is to understand if these treatments cause cognitive chang…

This study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…

This early-phase study is testing pirtobrutinib, a drug already approved for later-stage CLL/SLL, in 30 people who have not yet received any treatment. The main goal is to see how the drug changes immune cells in lymph nodes and blood, not to measure cure or symptom relief. Parti…

This study observes about 350 people with chronic lymphocytic leukemia (CLL) who received the drug acalabrutinib through a UK early access program. Researchers will review medical records to see how long patients went without their cancer worsening and how long they lived. No new…

This study follows 100 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) for two years to see how their quality of life, fatigue, and symptoms change after starting treatment. Researchers compare two drug types—BTK inhibitors and BCL-2 inhibitors—…

This study is a large registry that will follow nearly 3,000 people with blood cancers like chronic lymphocytic leukemia and several types of lymphoma. Researchers will collect information on treatments, how the disease progresses, and patients' quality of life over time. The goa…

This study is tracking 500 people with chronic lymphocytic leukemia (CLL) who are taking venetoclax, either alone or with other drugs, as part of their normal care in Austria, Germany, and Switzerland. Researchers want to see how well the treatment works in real-life settings and…